283 related articles for article (PubMed ID: 34603284)
1. Characterizing the Relationship Between Neutralization Sensitivity and
Wilson A; Shakhtour L; Ward A; Ren Y; Recarey M; Stevenson E; Korom M; Kovacs C; Benko E; Jones RB; Lynch RM
Front Immunol; 2021; 12():710327. PubMed ID: 34603284
[TBL] [Abstract][Full Text] [Related]
2. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T
J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881
[TBL] [Abstract][Full Text] [Related]
3. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
[TBL] [Abstract][Full Text] [Related]
4. Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants.
Martinez DR; Tu JJ; Kumar A; Mangold JF; Mangan RJ; Goswami R; Giorgi EE; Chen J; Mengual M; Douglas AO; Heimsath H; Saunders KO; Nicely NI; Eudailey J; Hernandez G; Morgan-Asiedu PK; Wiehe K; Haynes BF; Moody MA; LaBranche C; Montefiori DC; Gao F; Permar SR
mBio; 2020 Mar; 11(2):. PubMed ID: 32156815
[TBL] [Abstract][Full Text] [Related]
5. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
[TBL] [Abstract][Full Text] [Related]
6. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.
Nyanhete TE; Edwards RJ; LaBranche CC; Mansouri K; Eaton A; Dennison SM; Saunders KO; Goodman D; Janowska K; Spreng RL; Zhang L; Mudrak SV; Hope TJ; Hora B; Bradley T; Georgiev IS; Montefiori DC; Acharya P; Tomaras GD
Front Immunol; 2021; 12():670561. PubMed ID: 35003053
[TBL] [Abstract][Full Text] [Related]
7. Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.
Ringe R; Thakar M; Bhattacharya J
Retrovirology; 2010 Sep; 7():76. PubMed ID: 20860805
[TBL] [Abstract][Full Text] [Related]
8. Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir.
Yu WH; Su D; Torabi J; Fennessey CM; Shiakolas A; Lynch R; Chun TW; Doria-Rose N; Alter G; Seaman MS; Keele BF; Lauffenburger DA; Julg B
JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484826
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
10. Persistence of envelopes in different CD4+ T-cell subsets in antiretroviral therapy-suppressed people with HIV.
Gartner MJ; Tumpach C; Dantanarayana A; Stern J; Zerbato JM; Chang JJ; Angelovich TA; Anderson JL; Symons J; Deeks SG; Flynn JK; Lewin SR; Churchill MJ; Gorry PR; Roche M
AIDS; 2023 Feb; 37(2):247-257. PubMed ID: 36541637
[TBL] [Abstract][Full Text] [Related]
11. Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals.
Martin F; Marcelino JM; Palladino C; Bártolo I; Tracana S; Moranguinho I; Gonçalves P; Mateus R; Calado R; Borrego P; Leitner T; Clemente S; Taveira N
Microbiol Spectr; 2022 Dec; 10(6):e0163422. PubMed ID: 36445130
[TBL] [Abstract][Full Text] [Related]
12. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
[TBL] [Abstract][Full Text] [Related]
13. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1.
Bertagnolli LN; Varriale J; Sweet S; Brockhurst J; Simonetti FR; White J; Beg S; Lynn K; Mounzer K; Frank I; Tebas P; Bar KJ; Montaner LJ; Siliciano RF; Siliciano JD
Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32066-32077. PubMed ID: 33239444
[TBL] [Abstract][Full Text] [Related]
14. Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers.
Kumar A; Giorgi EE; Tu JJ; Martinez DR; Eudailey J; Mengual M; Honnayakanahalli Marichannegowda M; Van Dyke R; Gao F; Permar SR
PLoS Pathog; 2021 Apr; 17(4):e1009478. PubMed ID: 33798244
[TBL] [Abstract][Full Text] [Related]
15. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
16. A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.
Joshi VR; Claiborne DT; Pack ML; Power KA; Newman RM; Batorsky R; Bean DJ; Goroff MS; Lingwood D; Seaman MS; Rosenberg E; Allen TM
J Virol; 2024 Mar; 98(3):e0172023. PubMed ID: 38412036
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
[TBL] [Abstract][Full Text] [Related]
18. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
[TBL] [Abstract][Full Text] [Related]
19. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
Ren Y; Korom M; Truong R; Chan D; Huang SH; Kovacs CC; Benko E; Safrit JT; Lee J; Garbán H; Apps R; Goldstein H; Lynch RM; Jones RB
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
